Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model

References

• Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respirat J. 2014;43:343–373.
   PubMed Web of Science ®Google Scholar
• Elias JA, Lee CG, Zheng T, Ma B, Homer RJ, Zhu Z. New insights into the pathogenesis of asthma. J Clin Invest. 2003;111:291–297.
   PubMed Web of Science ®Google Scholar
• Harkness LM, Ashton AW, Burgess JK. Asthma is not only an airway disease, but also a vascular disease. Pharmacol Therapeut. 2015;148:17–33.
   PubMed Web of Science ®Google Scholar
• Lee KS, Min KH, Kim SR, Park SJ, Park HS, Jin GY, Lee YC. Vascular endothelial growth factor modulates matrix metalloproteinase-9 expression in asthma. Am J Respirat Crit Care Med. 2006;174:161–170.
   PubMed Web of Science ®Google Scholar
• Bergeron C, Tulic MK, Hamid Q. Airway remodelling in asthma: from benchside to clinical practice. Canadian Respirat J. 2010;17:e85–93.
   PubMed Web of Science ®Google Scholar
• Zanini A, Chetta A, Imperatori AS, Spanevello A, Olivieri D. The role of the bronchial microvasculature in the airway remodelling in asthma and COPD. Respirat Res. 2010;11:132.
   PubMed Web of Science ®Google Scholar
• Ribatti D, Puxeddu I, Crivellato E, Nico B, Vacca A, Levi-Schaffer F. Angiogenesis in asthma. Clin Exp Allergy: J Br Soc Allergy Clin Immunol. 2009;39:1815–1821.
   Google Scholar
• Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V, Kang MJ, Cohn L, Kim YK, McDonald DM, Elias JA. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med. 2004;10:1095–1103.
   PubMed Web of Science ®Google Scholar
• Ito I, Fixman ED, Asai K, Yoshida M, Gounni AS, Martin JG, Hamid Q. Platelet-derived growth factor and transforming growth factor-beta modulate the expression of matrix metalloproteinases and migratory function of human airway smooth muscle cells. Clin Exp Allergy: J Br Soc Allergy Clin Immunol. 2009;39:1370–1380.
   Google Scholar
• Bosse Y, Rola-Pleszczynski M. FGF2 in asthmatic airway-smooth-muscle-cell hyperplasia. Trends Mol Med. 2008;14:3–11.
   PubMed Web of Science ®Google Scholar
• Rhee CK, Kang JY, Park CK, Lee SY, Kwon SS, Kim YK, Yoon HK. Effect of nilotinib on airway remodeling in a murine model of chronic asthma. Exp. Lung Res. 2014;40:199–210.
   PubMed Web of Science ®Google Scholar
• Rangarajan S, Kurundkar A, Kurundkar D, Bernard K, Sanders YY, Ding Q, et al. Novel mechanisms for the antifibrotic action of nintedanib. Am J Respirat Cell Mol Biol. 2016;54:51–59.
   PubMed Web of Science ®Google Scholar
• Santos ES, Gomez JE, Raez LE. Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. Invest New Drugs. 2012;30:1261–1269.
   PubMed Web of Science ®Google Scholar
• Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Investigators IT, Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. New Eng J Med. 2014;370:2071–2082.
   PubMed Web of Science ®Google Scholar
• Huang M, Liu X, Du Q, Yao X, Yin KS. Inhibitory effects of sunitinib on ovalbumin-induced chronic experimental asthma in mice. Chinese Med J. 2009;122:1061–1066.
   PubMed Web of Science ®Google Scholar
• Yuksel H, Yilmaz O, Karaman M, Bagriyanik HA, Firinci F, Kiray M, Turkeli A, Karaman O. Role of vascular endothelial growth factor antagonism on airway remodeling in asthma. Ann Allergy, Asthma Immunol: Off Pub Am College Allergy, Asthma, Immunol. 2013;110:150–155.
   Google Scholar
• Smith R. Is VEGF a potential therapeutic target in asthma? Pneumologia. 2014;63(194):97–99.
   Google Scholar
• Rhee CK, Kim JW, Park CK, Kim JS, Kang JY, Kim SJ, et al. Effect of imatinib on airway smooth muscle thickening in a murine model of chronic asthma. Int Archives Allergy Immunol. 2011;155:243–251.
   PubMed Web of Science ®Google Scholar
• Padrid P, Snook S, Finucane T, Shiue P, Cozzi P, Solway J, Leff AR. Persistent airway hyperresponsiveness and histologic alterations after chronic antigen challenge in cats. Am J Respirat Crit Care Med. 1995;151:184–193.
   PubMed Web of Science ®Google Scholar
• Loo SL, Wark PA. Recent advances in understanding and managing asthma. F1000Res. 2016;23:5.
   Google Scholar
• Gras D, Bourdin A, Vachier I, de Senneville L, Bonnans C, Chanez P. An ex vivo model of severe asthma using reconstituted human bronchial epithelium. J Allergy Clin Immunol. 2012;129:1259–66 e1.
   PubMed Web of Science ®Google Scholar
• Landolina N, Gangwar RS, Levi-Schaffer F. Mast cells' integrated actions with eosinophils and fibroblasts in allergic inflammation: implications for therapy. Adv Immunol. 2015;125:41–85.
   Google Scholar
• Prakash YS. Airway smooth muscle in airway reactivity and remodeling: what have we learned? Am J Physiol Lung Cell Mol Physiol. 2013;305:L912–L933.
   PubMed Web of Science ®Google Scholar
• Lopez-Guisa JM, Powers C, File D, Cochrane E, Jimenez N, Debley JS. Airway epithelial cells from asthmatic children differentially express proremodeling factors. J Allergy clin Immunol. 2012;129:990–7 e6.
   PubMed Web of Science ®Google Scholar
• Kazi AS, Lotfi S, Goncharova EA, Tliba O, Amrani Y, Krymskaya VP, Lazaar AL. Vascular endothelial growth factor-induced secretion of fibronectin is ERK dependent. Am J Physiol Lung Cell Mol Physiol. 2004;286:L539–L545.
   PubMed Web of Science ®Google Scholar
• Lu J, Zhu Y, Feng W, Pan Y, Li S, Han D, Liu L, Xie X, Wang G, Li M. Platelet-derived growth factor mediates interleukin-13-induced collagen I production in mouse airway fibroblasts. J Biosci. 2014;39:693–700.
   PubMed Web of Science ®Google Scholar
• Al-Muhsen S, Johnson JR, Hamid Q. Remodeling in asthma. J Allergy Clin Immunol. 2011;128:451–462; quiz 63-4.
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774–4782.
   PubMed Web of Science ®Google Scholar
• Wuyts WA, Antoniou KM, Borensztajn K, Costabel U, Cottin V, Crestani B, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respirat Med. 2014;2:933–942.
   PubMed Web of Science ®Google Scholar
• Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Therapeutics. 2014;349:209–220.
   PubMed Web of Science ®Google Scholar
• Lehtonen ST, Veijola A, Karvonen H, Lappi-Blanco E, Sormunen R, Korpela S, Zagai U, Skold MC, Kaarteenaho R. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respiratory Res. 2016;17:14.
   PubMed Web of Science ®Google Scholar
• Yang ZC, Yi MJ, Ran N, Wang C, Fu P, Feng XY, Xu L, Qu ZH. Transforming growth factor-beta1 induces bronchial epithelial cells to mesenchymal transition by activating the Snail pathway and promotes airway remodeling in asthma. Mol Med Rep. 2013;8:1663–1668.
   PubMed Web of Science ®Google Scholar
• Milger K, Kneidinger N, Neurohr C, Reichenberger F, Behr J. Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF. Eur Respirat J. 2015;46:1217–1221.
   PubMed Web of Science ®Google Scholar
• Hughes G, Toellner H, Morris H, Leonard C, Chaudhuri N. Real world experiences: Pirfenidone and Nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med. 2016;5: E78.
   PubMed Web of Science ®Google Scholar